HOME >> BIOLOGY >> NEWS
After 2 years, study shows Revlimid patients live longer and remain transfusion free

Orlando, FL (December 11, 2006) -- Dr. Alan List, from the H. Lee Moffitt Cancer Center & Research Institute, presented the final results from a pivotal Phase II trial evaluating Revlimid in patients with an incurable blood cancer known as myelodysplastic syndromes (MDS) at this years American Society of Hematology (ASH) meeting. This breakthrough data showed that in MDS patients with chromosome 5q deletion treatment with Revlimid can provide long-term durable results and help them to achieve blood transfusion independence and remain transfusion free.

"These landmark data demonstrate that Revlimid, in many cases, eliminates all signs of the cancers genetic cause, on partial deletion of chromosome 5, and as a consequence reduce or even eliminate the need for transfusions in many patients with MDS. After over two years of follow up, these responses have sustained," said List, Professor of Oncology and Medicine and Chief, Division of Hematology Malignancies at Moffitt, and lead investigator of the study. "It is very rewarding to see patients treated with Revlimid, living longer, living three or four years transfusion free and having a better quality of life overall."

MDS, a cancer in which the bone marrow fails to make enough functioning blood cells, affects 300,000 people worldwide killing 60,000 to 70,000 a year. MDS patients suffer from anemia and fatigue and need whole-body blood transfusions as much as twice a month. Repeated transfusions can lead to a toxic buildup called "iron overload" that severely damages the heart, liver and pancreas, and patients eventually succumb to the disease.

The data presented by List showed that two-thirds of patients who received Revlimid were completely freed from the need for blood transfusions. More significantly, in 44 percent of patients, there was no detectable trace of the cancer and after two years of follow-up the median duration has not yet been achieved.

Additional data o
'"/>


11-Dec-2006


Page: 1 2

Related biology news :

1. After a decades-long search, scientists identify new genetic risk factors for multiple sclerosis
2. After scrutiny, preemie lung treatments turn out to be safe, effective
3. After North Korea test, what can be done to reduce the growing nuclear threat?
4. After insects attack, plants bunker sugars for later regrowth
5. After the Hurricanes
6. After the yeast is gone bacteria continue to develop flavor of sparkling wine
7. After a time-shift, mixed signals from the circadian clock
8. After flu exposure, mild exercise protects mature mice from dying
9. Allergy battle could be won in five years, says scientist
10. New study warns limited carbon market puts 20 percent of tropical forest at risk
11. Clones on task serve greater good, evolutionary study shows

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/15/2019)... ... , ... Serialization deadlines in the US and European Union ... becomes fully applied in the United States in 2023, pharmaceutical companies are scrutinizing ... most regulations?including the Drug Supply Chain Security Act (DSCSA)?have required minimal system capabilities. ...
(Date:8/14/2019)... , ... August 14, 2019 , ... Join Jonathan Riek, ... session on Tuesday, September 10, 2019 at 1pm EDT to learn about two ... effective management. , NAFLD is the most common diffuse liver disease, with a ...
(Date:8/14/2019)... ... , ... Dr. Julie Reck of Veterinary Medical Center of Fort Mill has recently ... cell patient, her own geriatric Australian Shepherd, Simon, was treated in June 2019 for osteoarthritis ... but his body was weak, and he struggled to play fetch and other games with ...
Breaking Biology News(10 mins):
(Date:8/8/2019)... ... August 08, 2019 , ... Inference Solutions , a ... today announced that the company’s Studio Intelligent Virtual Agent (IVA) platform earned ... will officially accept the award at Frost & Sullivan’s annual Excellence in Best ...
(Date:8/6/2019)... ... August 06, 2019 , ... ... populations down to the strain level, has announced partnerships with six international distributors. ... to companies and research organizations in Australia, Benelux, Indonesia, Korea, Malaysia, Myanmar, New ...
(Date:8/4/2019)... , ... August 02, 2019 , ... Cirtec Medical Corporation, ... devices, today announced that it has begun construction on a 30,000 sq. ft. ... miles from San Jose. , The facility, which is expected to be fully ...
(Date:7/23/2019)... ... July 22, 2019 , ... While today ... in the fields of 3D tissue imaging , digital pathology , ... started back in 2013 as a products company. These products are focused on ...
Breaking Biology Technology:
Cached News: